SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on March 6, 2003; DOI 10.1182/blood-2002-11-3343. This Article Full Text (PDF) All Versions of this Article: 2002-11-3343v1 102/1/43    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Smith, S. M Articles by Larson, R. A Search for Related Content PubMed PubMed Citation Articles by Smith, S. M Articles by Larson, R. A Related Collections Related Article in Blood Online Social Bookmarking                   What's this? Submitted November 7, 2002 Accepted February 5, 2003 Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series Sonali M Smith, Michelle M Le Beau, Dezheng Huo, Theodore Karrison, Ronald M Sobecks, John Anastasi, James W Vardiman, Janet D Rowley, and Richard A Larson* Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA Section of Hematopathology, University of Chicago, Chicago, IL, USA Department of Health Studies, University of Chicago, Chicago, IL, USA * Corresponding author; email: rlarson{at}medicine.bsd.uchicago.edu. Therapy-related myelodysplasia and myeloid leukemia (t-MDS/t-AML) is a distinctive clinical syndrome occurring after exposure to chemotherapy (CT) or radiotherapy (RT). We report on 306 consecutive patients referred to our institution with morphologic review and cytogenetic analyses. Since 1972, 141 males and 165 females with a median age of 51 years (range, 3-83) at primary diagnosis and 58 years (range, 6-86) at secondary diagnosis were analyzed. Patients had received various cytotoxic agents including alkylating agents (240 patients, 78%) and topoisomerase II inhibitors (115 patients, 39%). 121 (40%) had received CT alone, 43 (14%) had received RT alone, and 139 (45%) had received both modalities. At diagnosis of t-MDS/t-AML, 282 (92%) had clonal abnormalities involving chromosome 5 (n=63), chromosome 7 (n=85), both chromosomes 5 and 7 (n=66), recurring balanced rearrangements (n=31), other clonal abnormalities (n=39), or a normal karyotype (n=24). Abnormalities of chromosomes 5 and/or 7 accounted for 76% of all cases with an abnormal karyotype. Seventeen patients had developed t-MDS/t-AML after autologous stem cell transplantation, but no unique pattern of cytogenetic abnormalities was observed. A shorter latency was observed for patients with balanced rearrangements (median, 28 vs. 67 months; p<0.0001). Patients presenting with acute leukemia were more likely to have a balanced rearrangement compared with those presenting with myelodysplasia (28% vs. 4%, p<0.0001). Median survival after diagnosis of t-MDS/t-AML was eight months; survival at 5 years was less than 10%. These data confirm and extend previous associations between clinical, morphological, and cytogenetic findings in t-MDS/t-AML. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Secondary leukemia or unfavorable leukemia? Jacob M. Rowe Blood 2003 102: 1. [Full Text] [PDF] This article has been cited by other articles: R. V. Tiu, L. P. Gondek, C. L. O'Keefe, J. Huh, M. A. Sekeres, P. Elson, M. A. McDevitt, X. F. Wang, M. J. Levis, J. E. Karp, et al. New Lesions Detected by Single Nucleotide Polymorphism Array-Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia J. Clin. Oncol., November 1, 2009; 27(31): 5219 - 5226. [Abstract] [Full Text] [PDF] M. Czader and A. Orazi Therapy-Related Myeloid Neoplasms Am J Clin Pathol, September 1, 2009; 132(3): 410 - 425. [Abstract] [Full Text] [PDF] J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood, July 30, 2009; 114(5): 937 - 951. [Abstract] [Full Text] [PDF] R. M. Stone How I treat patients with myelodysplastic syndromes Blood, June 18, 2009; 113(25): 6296 - 6303. [Full Text] [PDF] J. A. Knight, A. D. Skol, A. Shinde, D. Hastings, R. A. Walgren, J. Shao, T. R. Tennant, M. Banerjee, J. M. Allan, M. M. Le Beau, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility Blood, May 28, 2009; 113(22): 5575 - 5582. [Abstract] [Full Text] [PDF] S. A. Gustafson, P. Lin, S. S. Chen, L. Chen, L. V. Abruzzo, R. Luthra, L. J. Medeiros, and S. A. Wang Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome Am J Clin Pathol, May 1, 2009; 131(5): 647 - 655. [Abstract] [Full Text] [PDF] R. A. Larson Therapy-related myeloid neoplasms Haematologica, April 1, 2009; 94(4): 454 - 459. [Full Text] [PDF] N. Kroger, R. Brand, A. van Biezen, A. Zander, J. Dierlamm, D. Niederwieser, A. Devergie, T. Ruutu, J. Cornish, P. Ljungman, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation Haematologica, April 1, 2009; 94(4): 542 - 549. [Abstract] [Full Text] [PDF] M. A. Sanz, D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Buchner, H. Dohner, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, February 26, 2009; 113(9): 1875 - 1891. [Abstract] [Full Text] [PDF] X. Leleu, J. Soumerai, A. Roccaro, E. Hatjiharissi, Z. R. Hunter, R. Manning, B. T. Ciccarelli, A. Sacco, L. Ioakimidis, S. Adamia, et al. Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenstrom Macroglobulinemia Treated With Nucleoside Analogs J. Clin. Oncol., January 10, 2009; 27(2): 250 - 255. [Abstract] [Full Text] [PDF] R. Shivakumar, W. Tan, G. E. Wilding, E. S. Wang, and M. Wetzler Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases Ann. Onc., September 1, 2008; 19(9): 1634 - 1638. [Abstract] [Full Text] [PDF] N. A. Ellis, D. Huo, O. Yildiz, L. J. Worrillow, M. Banerjee, M. M. Le Beau, R. A. Larson, J. M. Allan, and K. Onel MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility Blood, August 1, 2008; 112(3): 741 - 749. [Abstract] [Full Text] [PDF] M. A. Lichtman Is There an Entity of Chemically Induced BCR-ABL-Positive Chronic Myelogenous Leukemia? Oncologist, June 1, 2008; 13(6): 645 - 654. [Abstract] [Full Text] [PDF] M. A. Lichtman Battling the Hematological Malignancies: The 200 Years' War Oncologist, February 1, 2008; 13(2): 126 - 138. [Abstract] [Full Text] [PDF] G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso Therapy-related leukemia and myelodysplasia: susceptibility and incidence Haematologica, October 1, 2007; 92(10): 1389 - 1398. [Abstract] [Full Text] [PDF] M. S. Czuczman, C. Emmanouilides, M. Darif, T. E. Witzig, L. I. Gordon, S. Revell, K. Vo, and A. Molina Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy J. Clin. Oncol., September 20, 2007; 25(27): 4285 - 4292. [Abstract] [Full Text] [PDF] C. Chang, B. E. Storer, B. L. Scott, E. M. Bryant, H. M. Shulman, M. E. Flowers, B. M. Sandmaier, R. P. Witherspoon, R. A. Nash, J. E. Sanders, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders Blood, August 15, 2007; 110(4): 1379 - 1387. [Abstract] [Full Text] [PDF] J. M. Joslin, A. A. Fernald, T. R. Tennant, E. M. Davis, S. C. Kogan, J. Anastasi, J. D. Crispino, and M. M. Le Beau Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders Blood, July 15, 2007; 110(2): 719 - 726. [Abstract] [Full Text] [PDF] I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood, April 1, 2007; 109(7): 2781 - 2790. [Abstract] [Full Text] [PDF] S. Agrawal, M. Unterberg, S. Koschmieder, U. zur Stadt, U. Brunnberg, W. Verbeek, T. Buchner, W. E. Berdel, H. Serve, and C. Muller-Tidow DNA Methylation of Tumor Suppressor Genes in Clinical Remission Predicts the Relapse Risk in Acute Myeloid Leukemia Cancer Res., February 1, 2007; 67(3): 1370 - 1377. [Abstract] [Full Text] [PDF] J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 392 - 397. [Abstract] [Full Text] [PDF] R. A. Larson Etiology and Management of Therapy-Related Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 453 - 459. [Abstract] [Full Text] [PDF] K. Shannon and L. R. Silverman Myelodysplastic syndrome and overlap syndromes ASH Self-Assessment Program, January 1, 2007; 2007(1): 228 - 242. [Full Text] [PDF] M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia J. Clin. Oncol., August 1, 2006; 24(22): 3604 - 3610. [Abstract] [Full Text] [PDF] V. Noronha, N. Berliner, K. K. Ballen, J. Lacy, J. Kracher, J. Baehring, and J. W. Henson Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature Neuro-oncol, July 1, 2006; 8(3): 280 - 283. [Abstract] [Full Text] [PDF] H. Geiger, D. Schleimer, K. J. Nattamai, S. R. Dannenmann, S. M. Davies, and B. D. Weiss Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood, April 1, 2006; 107(7): 3010 - 3011. [Full Text] [PDF] D. P. Steensma and J. M. Bennett The Myelodysplastic Syndromes: Diagnosis and Treatment Mayo Clin. Proc., January 1, 2006; 81(1): 104 - 130. [Abstract] [Full Text] [PDF] Z. Qian, L. Mao, and M. Lebeau Genetic Pathways in Therapy-Related Leukemia: FHL2 Cooperates with del(5q). Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 648 - 648. [Abstract] D. P. Steensma and A. F. List Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity Mayo Clin. Proc., May 1, 2005; 80(5): 681 - 698. [Abstract] [PDF] S. E. Craven, D. French, W. Ye, F. de Sauvage, and A. Rosenthal Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome Blood, May 1, 2005; 105(9): 3528 - 3534. [Abstract] [Full Text] [PDF] A. R. Mistry, C. A. Felix, R. J. Whitmarsh, A. Mason, A. Reiter, B. Cassinat, A. Parry, C. Walz, J. L. Wiemels, M. R. Segal, et al. DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia N. Engl. J. Med., April 14, 2005; 352(15): 1529 - 1538. [Abstract] [Full Text] [PDF] L. Pagano, A. Pulsoni, M. Vignetti, M. E. Tosti, P. Falcucci, P. Fazi, L. Fianchi, A. Levis, A. Bosi, E. Angelucci, et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials Ann. Onc., February 1, 2005; 16(2): 228 - 233. [Abstract] [Full Text] [PDF] J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood, February 1, 2005; 105(3): 959 - 967. [Abstract] [Full Text] [PDF] A. Tichelli and G. Socie Considerations for Adult Cancer Survivors Hematology, January 1, 2005; 2005(1): 516 - 522. [Abstract] [Full Text] [PDF] D. H. Christiansen, M. K. Andersen, and J. Pedersen-Bjergaard Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation Blood, September 1, 2004; 104(5): 1474 - 1481. [Abstract] [Full Text] [PDF] R. A. Larson Therapy-related myeloid leukemia: stochastic or idiosyncratic? Blood, August 1, 2004; 104(3): 602 - 603. [Full Text] [PDF] W. Kern, T. Haferlach, S. Schnittger, W. Hiddemann, and C. Schoch Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of Karyotype J. Clin. Oncol., June 15, 2004; 22(12): 2510 - 2511. [Full Text] [PDF] M. T. Voso, A. Scardocci, F. Guidi, G. Zini, A. Di Mario, L. Pagano, S. Hohaus, and G. Leone Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes Blood, January 15, 2004; 103(2): 698 - 700. [Abstract] [Full Text] [PDF] B. D. Cheson, J. M. Bennett, K. J. Kopecky, T. Buchner, C. L. Willman, E. H. Estey, C. A. Schiffer, H. Doehner, M. S. Tallman, T. A. Lister, et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J. Clin. Oncol., December 15, 2003; 21(24): 4642 - 4649. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020